Skip to main content
Top
Published in: Current Colorectal Cancer Reports 6/2017

01-12-2017 | Author Correction

Author Correction: Chemoprevention of Colorectal Cancer in High-Risk Patients: from Molecular Targets to Clinical Trials

Authors: Dora Colussi, Franco Bazzoli, Luigi Ricciardiello

Published in: Current Colorectal Cancer Reports | Issue 6/2017

Login to get access

Excerpt

Author Correction: Curr Colorectal Cancer Rep (2017) 13:192-204
Metadata
Title
Author Correction: Chemoprevention of Colorectal Cancer in High-Risk Patients: from Molecular Targets to Clinical Trials
Authors
Dora Colussi
Franco Bazzoli
Luigi Ricciardiello
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 6/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0392-3

Other articles of this Issue 6/2017

Current Colorectal Cancer Reports 6/2017 Go to the issue

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Stool- and Blood-Based Molecular Tests in Screening for Colorectal Cancer: Ready for Prime Time?

Diagnostic and Interventional Radiology Innovations in Colorectal Cancer (G de Prisco, Section Editor)

Liver Imaging for Colorectal Cancer Metastases

Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine